<DOC>
	<DOCNO>NCT01494766</DOCNO>
	<brief_summary>Tyrosine non essential amino acid precursor neurotransmitter , dopamine . Tyrosine convert Levodihydrophenylalanine ( L-Dopa ) L-Dopa subsequently avidly converted dopamine . It well know dopamine deficiency lead manifestation restless legs syndrome ( RLS ) . Studies show dopamine agonist L-dopa effective controlling symptom . No study date do determine role tyrosine RLS . This open-label pilot study aim determine efficacy tolerability tyrosine RLS , current agent limitation treat RLS addition add another possible agent investigator arsenal treat RLS maybe cost efficient . In pilot study , dose tyrosine escalate 750 mg daily mouth ( PO ) 3000 mg daily PO , tolerate , increment 750 mg every week patient meet inclusion criterion RLS . Patients ' symptom monitor weekly basis six week .</brief_summary>
	<brief_title>Efficacy Tyrosine Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>1 . Men woman age 18 80 year 2 . Newly diagnose ( medicationnaïve ) restless legs syndrome ( use International Restless Legs Syndrome Study Group ( IRLSSG20 ) diagnostic criterion score great equal 15 , see Appendix A ) 3 . That interfere sleep onset and/or maintenance great four nights/week minimum six month 4 . Currently receive treatment RLS 1 . Patients suffer secondary RLS ( movement and/or primary sleep disorder , chronic renal insufficiency calculate creatinine clearance , and/or iron deficiency baseline serum ferritin level le 10 ng/ml ) 2 . Patients currently pharmacotherapy RLS ( medicationnaïve ) previous use pharmacotherapy RLS past 3 . Patients pregnant and/or breastfeed 4 . Patients levothyroxine monoamine oxidase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>RLS</keyword>
</DOC>